Biogen Idec Inc. announced on October 9th that it was discontinuing development of its investigational rheumatoid arthritis (RA) drug baminercept after if failed to meet Phase II study endpoints. [...]
|
|||||||
 |
Earlier this year British researchers raised a concern that anti-TNF drugs, as a result of their action in depressing the immune system, may increase the overall risk of cancer. Spanish researchers who are presenting their research at the American College of Rheumatology’s annual meeting in San Francisco say their studies do not support that conclusion. [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments